Shares of other companies:
May 1, 2024 Inflation Persistence: No Fed Rate Cuts in Sight
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
3M Stock: Dividend Likely Cut In Half
May 1, 2024
Amazon Q1 Review: Best Of Big Tech Bunch
April 30, 2024
Tesla: The Thesis Is Stronger Than Ever
April 30, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
FATE Stock News and Mentions of Fate Therapeutics, Inc. Stocktwits
Updated: May 2, 2024 (11:06)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Fate Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Fate Therapeutics, Inc. (FATE).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Fate Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Fate Therapeutics, Inc. (FATE)
April 22, 2024 (20:30) / "GlobeNewswire" (by Fate Therapeutics)
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
Key Therapeutic Mechanisms of Clinical Activity for Autoimmune Diseases, including B cell Depletion, Tissue Infiltration and Immune Reconstitution Data, from Phase 1 Study of FT819 in Relapsed / Refractory B-cell Malignancies to be Highlighted ...
In Article Trend: Neutral
April 22, 2024 (18:39) / "Zacks Commentary" (by Zacks Equity Research)
How Should You Play Merck ( MRK ) Stock Ahead of Q1 Earnings?
Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports first-quarter 2024 earnings.
In Article Trend: Somewhat-Bullish
April 22, 2024 (17:57) / "Zacks Commentary" (by Zacks Equity Research)
Gilead ( GILD ) Gears Up to Report Q1 Earnings: What to Expect?
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
In Article Trend: Neutral
April 22, 2024 (17:56) / "Zacks Commentary" (by Zacks Equity Research)
Bristol-Myers' ( BMY ) to Report Q1 Earnings: What You Should Know
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
In Article Trend: Somewhat-Bullish
April 19, 2024 (14:10) / "Zacks Commentary" (by Ekta Bagri)
Novartis ( NVS ) to Report Q1 Earnings: What to Expect?
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
In Article Trend: Somewhat-Bullish
April 19, 2024 (13:39) / "Zacks Commentary" (by Zacks Equity Research)
What's in Store for Biogen ( BIIB ) This Earnings Season?
Biogen's (BIIB) sales in the first quarter are likely to have been hurt by lower sales of its multiple sclerosis drugs, while sales of Spinraza are likely to have been moderate.
In Article Trend: Neutral
April 12, 2024 (13:09) / "Zacks Commentary" (by Zacks Equity Research)
J&J ( JNJ ) to Begin Pharma Q1 Earnings Season: What's in Store?
J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.
In Article Trend: Somewhat-Bullish
April 6, 2024 (06:17) / "Zacks Commentary" (by Zacks Equity Research)
Fate Therapeutics ( FATE ) Surges 86.4% YTD on Pipeline Progress
Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
In Article Trend: Somewhat-Bullish
March 29, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Amicus Therapeutics ( FOLD ) Down 8.1% Since Last Earnings Report?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 28, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Why Is Myriad ( MYGN ) Down 1% Since Last Earnings Report?
Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 27, 2024 (15:30) / "Zacks Commentary" (by Zacks Equity Research)
Fate Therapeutics ( FATE ) Down 8% Since Last Earnings Report: Can It Rebound?
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
In Article Trend: Neutral
March 19, 2024 (12:44) / "Benzinga" (by Globe Newswire)
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement - Fate Therapeutics ( NASDAQ:FATE )
SAN DIEGO, March 19, 2024 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. ( the "Company" or "Fate Therapeutics" ) FATE, a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell ( iPSC ) -derived cellular immunotherapies to ...
In Article Trend: Somewhat-Bullish
March 19, 2024 (12:44) / "GlobeNewswire" (by Inc.)
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
SAN DIEGO, March 19, 2024 ( GLOBE NEWSWIRE ) -- Fate Therapeutics, Inc. ( the "Company" or "Fate Therapeutics" ) ( NASDAQ: FATE ) , a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell ( iPSC ) -derived cellular ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website